Central nervous system drug evaluation using positron emission tomography

Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
Mizuho SekineTetsuya Suhara

Abstract

In conventional pharmacological research in the field of mental disorders, pharmacological effect and dose have been estimated by ethological approach and in vitro data of affinity to the site of action. In addition, the frequency of administration has been estimated from drug kinetics in blood. However, there is a problem regarding an objective index of drug effects in the living body. Furthermore, the possibility that the concentration of drug in blood does not necessarily reflect the drug kinetics in target organs has been pointed out. Positron emission tomography (PET) techniques have made progress for more than 20 years, and made it possible to measure the distribution and kinetics of small molecule components in living brain. In this article, we focused on rational drug dosing using receptor occupancy and proof-of-concept of drugs in the drug development process using PET.

References

Aug 16, 1997·Lancet·Lyn S PilowskyR W Kerwin
Jul 11, 1998·The American Journal of Psychiatry·S KapurSylvain Houle
Aug 5, 1998·Journal of Clinical Psychopharmacology·A L Nordström, Lars Farde
Apr 9, 2001·Psychopharmacology·Fumihiko YasunoShuji Tanada
Jul 28, 2001·Physics in Medicine and Biology·C TaiS R Cherry
Dec 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·X XiberasM L Paillère-Martinot
Jul 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fuji YokoiDean F Wong
Jan 22, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Christof KnoessWolf-Dieter Heiss
Jan 25, 2003·Journal of Clinical Psychopharmacology·Rodrigo A BressanLyn S Pilowsky
Oct 15, 2003·Archives of General Psychiatry·Gerhard GründerDean F Wong
Feb 7, 2004·The International Journal of Neuropsychopharmacology·Akihiro TakanoYoshiro Okubo
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerhard GründerPeter Bartenstein
Nov 18, 2005·The International Journal of Neuropsychopharmacology·Akihiro TakanoYoshiro Okubo
Mar 1, 2006·Psychopharmacology·Akihiro TakanoTetsuya Suhara
Apr 25, 2006·Journal of Clinical Psychopharmacology·Akihiro TakanoKazutoshi Suzuki
Sep 13, 2006·Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy·Yukitsuka Kudo
Oct 6, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Joji TokugawaWilliam C Eckelman
Apr 3, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yukitsuka KudoHiroyuki Arai
Oct 3, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Akihiro TakanoChrister Halldin
Jan 4, 2008·ILAR Journal·Isabel J HildebrandtWolfgang A Weber
Jul 18, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ryosuke ArakawaTetsuya Suhara
Feb 25, 2009·The International Journal of Neuropsychopharmacology·Takeaki SaijoTetsuya Suhara
Jun 6, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Svante NybergLars Farde
Oct 20, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Seok Rye ChoiHank F Kung
Oct 24, 2009·European Archives of Psychiatry and Clinical Neuroscience·Ryosuke ArakawaTetsuya Suhara
May 27, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Dean F WongMichael J Pontecorvo

Citations

Mar 24, 2017·Brain : a Journal of Neurology·Suzanne ReevesRobert Howard

Related Concepts

Mental Disorders
Blood
Brain
Positron-Emission Tomography
Research
Organ
Site
Evaluation
Receptor
Drug Development

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.